Loading...
XASXANR
Market cap6mUSD
Dec 27, Last price  
0.05AUD
1D
11.90%
1Q
-32.86%
Jan 2017
-95.52%
IPO
-87.30%
Name

Anatara Lifesciences Ltd

Chart & Performance

D1W1MN
XASX:ANR chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.52%
Rev. gr., 5y
26.97%
Revenues
0k
90,00090,00061,3832,448,3412,853,7446,467663,40500000
Net income
-1m
L-28.27%
-185,394-862,856-1,795,228-723,934-1,705,002-3,569,016-2,868,272-3,364,644-1,995,874-2,532,293-2,023,188-1,451,242
CFO
-1m
L-44.75%
-177,219-639,266-1,924,611-280,366-2,878,558-3,315,146-2,237,655-2,724,899-2,097,477-2,232,876-2,257,896-1,247,396
Earnings
Feb 26, 2025

Profile

Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry water. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.
URL
https://anataralifesciences.com/
IPO date
Oct 16, 2014
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
Cost of revenue
2,852
3,285
3,022
Unusual Expense (Income)
NOPBT
(2,852)
(3,285)
(3,022)
NOPBT Margin
Operating Taxes
(626)
(1,215)
(469)
Tax Rate
NOPAT
(2,226)
(2,070)
(2,554)
Net income
(1,451)
-28.27%
(2,023)
-20.10%
(2,532)
26.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,985
1,320
(10)
BB yield
-31.51%
-45.20%
0.23%
Debt
Debt current
21
Long-term debt
90
Deferred revenue
Other long-term liabilities
3
80
Net debt
(982)
(401)
(1,059)
Cash flow
Cash from operating activities
(1,247)
(2,258)
(2,233)
CAPEX
(2)
(7)
Cash from investing activities
50
(2)
(57)
Cash from financing activities
1,828
1,491
(22)
FCF
(2,087)
(2,334)
(2,307)
Balance
Cash
982
401
1,170
Long term investments
Excess cash
982
401
1,170
Stockholders' equity
1,365
925
1,364
Invested Capital
385
524
260
ROIC
ROCE
EV
Common stock shares outstanding
150,017
104,303
78,218
Price
0.04
50.00%
0.03
-49.09%
0.06
-64.52%
Market cap
6,301
115.74%
2,920
-32.11%
4,302
-59.75%
EV
5,319
2,519
3,243
EBITDA
(2,850)
(3,260)
(2,998)
EV/EBITDA
Interest
2
3
Interest/NOPBT